Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.

Bioorganic & medicinal chemistry letters - 15 Sept 2016

Zhong Min, Peng Eric, Huang Ningwu, Huang Qi, Huq Anja, Lau Meiyen, Colonno Richard, Li Leping

Abstract excerpt

This Letter describes the synthesis, representative structure activity relationship (SAR), activity and PK profiles of a series of functionalized benzimidazole-naphthylene-imidazole derivatives as HCV NS5A inhibitors. This effort successfully led to the discovery of ravidasvir (PPI-668), which has been well tolerated and shown high sustained viral response rates as a key component in all-oral combination regimens...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Macaca fascicularis

Share to Structure-Activity Relationship

Share to Valine

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 27506559
DOI: 10.1016/j.bmcl.2016.07.066

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.PMID 27506559Read ↗

Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).Semantic proximity Read ↗

Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.Semantic proximity Read ↗

Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs.Semantic proximity Read ↗

Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.Semantic proximity Read ↗

Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.Semantic proximity Read ↗

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment.Semantic proximity Read ↗

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Semantic proximity Read ↗

Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor.Semantic proximity Read ↗

Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.Semantic proximity Read ↗

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.Semantic proximity Read ↗

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.